Alpha 2.0
Login Register
» Articles » PMID: 35580946

Delayed Drug Hypersensitivity Reaction to Secukinumab in a Patient with Hidradenitis Suppurativa

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2022 May 17
PMID 35580946
Authors
Sasank Konda
Nayha Shetty
Ben Friedman
Jesse Veenstra
Affiliations
Soon will be listed here.
Abstract

A woman in her 30s presented to the dermatology clinic with widespread, pruritic, red papules and plaques involving the ears, trunk and extremities. The rash developed a few days after receiving her second injection of secukinumab, which was initiated for recalcitrant Hurley stage III hidradenitis suppurativa. Investigations revealed a psoriasiform drug hypersensitivity reaction secondary to secukinumab. In this report, we describe the clinical course, histopathological correlation and treatment of this rarely documented reaction.

Citing Articles

Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.

Fragoso N, Masson R, Gillenwater T, Shi V, Hsiao J Dermatol Ther (Heidelb). 2023; 13(8):1661-1697.

PMID: 37402031 PMC: 10366071. DOI: 10.1007/s13555-023-00956-6.

References
1.
Darrigade A, Dendooven E, Mangodt E, Aerts O . Delayed-type hypersensitivity to secukinumab with tolerance to ixekizumab. J Allergy Clin Immunol Pract. 2020; 8(10):3626-3628. DOI: 10.1016/j.jaip.2020.06.016. View
2.
Peigottu M, Montesu M . Adverse skin reaction to Secukinumab. J Eur Acad Dermatol Venereol. 2017; 31(10):e432-e433. DOI: 10.1111/jdv.14248. View
3.
Karle A, Spindeldreher S, Kolbinger F . Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016; 8(3):536-50. PMC: 4966846. DOI: 10.1080/19420862.2015.1136761. View
4.
Wong S, Chung H . Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions. J Clin Rheumatol. 2019; 26(6):e197-e198. DOI: 10.1097/RHU.0000000000001065. View
5.
Shibata M, Sawada Y, Yamaguchi T, Ohmori S, Omoto D, Haruyama S . Drug eruption caused by secukinumab. Eur J Dermatol. 2016; 27(1):67-68. DOI: 10.1684/ejd.2016.2900. View